FindTrial
Sign In

Evaluation the efficiency and safety of intravenous tranexamic acid protocol for reducing the hidden blood loss in primary unilateral total knee arthroplasty

Evaluation the efficiency and safety of intravenous tranexamic acid protocol for reducing the hidden blood loss in primary unilateral total knee arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005705
Enrollment
Unknown
Registered
2014-06-04
Start date
2014-06-04
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary osteoarthritis of the knee

Interventions

TA:Intravenous usage of the tranexamic acid for 3 days after TKA
P:Placebo

Sponsors

Peking University 3rd Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: primary OA, unilateral TKA, Livaxsabine, no DVT detected in B-US prior the surgery, GII prothectic, patient informed consent

Exclusion criteria

Exclusion criteria: Any other disease, severe valgus or varus deformity (larger than 20 degree), non-GII prothetic, bi-lateral or revision surgery, no use of livaxabine, detective DVT by B-US, blood tendency or usage, malnurtration, infection recently, with DM or venous diseases

Design outcomes

Secondary

MeasureTime frame
Circumference of the lower limber;—

Primary

MeasureTime frame
hemoglobin;HCT;Incidence of DVT;—

Contacts

Public ContactMinwei Zhao
18611165078@163.com+86 18611165078

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026